International Clinical Trial: Clinical study of inelizumab in the treatment of AQP4-IgG-positive neuromyelitis optica spectrum disorder

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132843) titled 'Clinical study of inelizumab in the treatment of AQP4-IgG-positive neuromyelitis optica spectrum disorder' on Sept. 18.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: The Affiliated Hospital of Xuzhou Medical University

Condition: AQP4-IgG positive neuromyelitis optica spectrum disorder

Intervention: Early-onset:None

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-30

Target Sample Size: Early-onset:15;Late-onset:15;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=317366

Published by HT ...